Another great place to shop for London Prog products is Amazon. They have more than just books!
 |
Candle Song EP (IMPORT)
Sale Price: $23.99
|
|
|
Tracks: 1.Candle Song-3:20(Single Edit) 2.Alive & Well-4:42 3.Change We Must-5:38(Album Edit) RARE, out of prink UK EP, issued in a slim-line case, complete with insert.
|
 |
The Pragmatic Programmer: From Journeyman to Master
List Price: $49.99
Sale Price: $32.84
|
|
|
Programmers are craftspeople trained to use a certain set of tools (editors, object managers, version trackers) to generate a certain kind of product (programs) that will operate in some environment (operating systems on hardware assemblies). Like any other craft, computer programming has spawned a body of wisdom, most of which isn't taught at universities or in certification classes. Most programmers arrive at the so-called tricks of the trade over time, through independent experimentation. In The Pragmatic Programmer, Andrew Hunt and David Thomas codify many of the truths they've discovered during their respective careers as designers of software and writers of code. Some of the authors' nuggets of pragmatism are concrete, and the path to their implementation is clear. They advise readers to learn one text editor, for example, and use it for everything. They also recommend the use of version-tracking software for even the smallest projects, and promote the merits of learning regular expression syntax and a text-manipulation language. Other (perhaps more valuable) advice is more light-hearted. In the debugging section, it is noted that, "if you see hoof prints think horses, not zebras." That is, suspect everything, but start looking for problems in the most obvious places. There are recommendations for making estimates of time and expense, and for integrating testing into the development process. You'll want a copy of The Pragmatic Programmer for two reasons: it displays your own accumulated wisdom more cleanly than you ever bothered to state it, and it introduces you to methods of work that you may not yet have considered. Working programmers will enjoy this book. --David Wall Topics covered: A useful approach to software design and construction that allows for efficient, profitable development of high-quality products. Elements of the approach include specification development, customer relations, team management, design practices, development tools, and testing procedures. This approach is presented with the help of anecdotes and technical problems.
What others in the trenches say about The Pragmatic Programmer..."The cool thing about this book is that it's great for keeping the programming process fresh. The book helps you to continue to grow and clearly comes from people who have been there." --Kent Beck, author of Extreme Programming Explained: Embrace Change "I found this book to be a great mix of solid advice and wonderful analogies!" --Martin Fowler, author of Refactoring and UML Distilled "I would buy a copy, read it twice, then tell all my colleagues to run out and grab a copy. This is a book I would never loan because I would worry about it being lost." --Kevin Ruland, Management Science, MSG-Logistics "The wisdom and practical experience of the authors is obvious. The topics presented are relevant and useful...By far its greatest strength for me has been the outstanding analogies--tracer bullets, broken windows, and the fabulous helicopter-based explanation of the need for orthogonality, especially in a crisis situation. I have little doubt that this book will eventually become an excellent source of useful information for journeymen programmers and expert mentors alike."--John Lakos, author of Large-Scale C++ Software Design "This is the sort of book I will buy a dozen copies of when it comes out so I can give it to my clients. " --Eric Vought, Software Engineer "Most modern books on software development fail to cover the basics of what makes a great software developer, instead spending their time on syntax or technology where in reality the greatest leverage possible for any software team is in having talented developers who really know their craft well. An excellent book." --Pete McBreen, Independent Consultant "Since reading this book, I have implemented many of the practical suggestions and tips it contains. Across the board, they have saved my company time and money while helping me get my job done quicker! This should be a desktop reference for everyone who works with code for a living." --Jared Richardson, Senior Software Developer, iRenaissance, Inc. "I would like to see this issued to every new employee at my company..." --Chris Cleeland, Senior Software Engineer, Object Computing, Inc. "If I'm putting together a project, it's the authors of this book that I want...And failing that I'd settle for people who've read their book."--Ward Cunningham Straight from the programming trenches, The Pragmatic Programmer cuts through the increasing specialization and technicalities of modern software development to examine the core process--taking a requirement and producing working, maintainable code that delights its users. It covers topics ranging from personal responsibility and career development to architectural techniques for keeping your code flexible and easy to adapt and reuse. Read this book, and you'll learn how to *Fight software rot; *Avoid the trap of duplicating knowledge; *Write flexible, dynamic, and adaptable code; *Avoid programming by coincidence; *Bullet-proof your code with contracts, assertions, and exceptions; *Capture real requirements; *Test ruthlessly and effectively; *Delight your users; *Build teams of pragmatic programmers; and *Make your developments more precise with automation. Written as a series of self-contained sections and filled with entertaining anecdotes, thoughtful examples, and interesting analogies, The Pragmatic Programmer illustrates the best practices and major pitfalls of many different aspects of software development.Whether you're a new coder, an experienced programmer, or a manager responsible for software projects, use these lessons daily, and you'll quickly see improvements in personal productivity, accuracy, and job satisfaction. You'll learn skills and develop habits and attitudes that form the foundation for long-term success in your career. You'll become a Pragmatic Programmer.
|
 |
More Rock Family Trees
List Price: $21.95
Sale Price: $19.01
|
|
|
This unique hand-drawn book is the latest in the Family Trees series. Traces the history of bands from every musical era including Buddy Holly, Black Sabbath, The Smiths, and Black Grape. Exhaustively researched and endlessly fascinating.
|
 |
Introduction to Computing and Programming in Python, A Multimedia Approach (2nd Edition)
List Price: $99.00
Sale Price: $45.00
|
|
|
For courses in Introduction to Computing or Introduction to Programming. There is a growing interest in computing for non-CS majors, or for students who have not yet determined their majors (sometimes called the “CS0” market). Computer science professors are also confronted with increased attrition and failure rates. Guzdial introduces programming as a way of creating and manipulating media–a context familiar and intriguing to today’s students. Students begin actual programming early on (sometimes over 100 lines of code in the second assignment). Guzdial’s approach has met with substantial success in class testing.
|
Amazon.Com
Here are some more information for London Prog:
Music fans can rock out all the way from Budapest airport to city with a shuttle tour of the area's hot and happening music hotspots. As both an airport shuttle driver and music fan I thought I'd share a few of my favourite places in the city. So buckle up your seatbelt and let's get ready to rock and roll.
Frank Zappa was a huge fan of Budapest and the city was luckily enough to house one of his last ever concerts back in 1991. I remember the day like it was yesterday, although I was only a young university student at the time. He was playing a concert to commemorate the removal of Soviet troops from Hungary, and with the town mayor present it was certainly an historic occasion. What made it even more fantastic was that he joined some local gipsy bands on stage and started jamming with them. My friend, Czigany, plays accordion in one of these bands and nearly 20 years later she still talks about the day that she jammed with Zappa on stage.
As Frank Zappa commemorated such an important occasion in our city's history we like to commemorate him in return, and what better way to do this than with the Zappa Cafe. I've taken many tourists here on my Budapest airport to city runs and whilst it may be popular, every rocker worth their weight in salt knows that it is the place to start an evening. I'd recommend sampling the hearty beef stew, but if you're just here for the beer then make like the locals and try the plum palinska. But be warned it isn't for the faint-hearted!
The underground hall in the Zappa Cafe has its own stage and usually has its own live music on a weeknight. Just recently we had a Hungarian band called the Magic Cats playing and these were a big hit with the locals. If there's no music on at the Zappa Cafe then we'll head over to Rocktogon, known for its acoustic sessions and chilled out atmosphere. When live bands are not playing, the atmosphere shifts and the DJ can often be found putting on loud punk music and heavy rock and roll which is guaranteed to have the crowd moshing until the early hours. If that all sounds a little too hardcore for you, then you can sway along to lighter rock at the disco sessions that take place regularly between 8pm and 11.30pm.
My shuttle rounds aren't always from Budapest airport to city and I have been known to drive a bit further afield. The Raday is located slightly out of town but I'd definitely recommend it to anyone with a love of music. It's more of a pub than a bustling nightclub, but it's great place to enjoy a couple of beers whilst sticking a tune on the old juke box.
If my Budapest airport to city passengers ask, I won't hesitate to recommend them some great Hungarian rock music. The punk band, CPG are a particular favourite of mine and were one of the first bands in Hungary to be arrested for rock-related subversion, spending two years in prison for political incitement. The prog rock band, Panta Rhei, and metal group, Fallenintoashes are also very good. But don't take my word for it; book a trip to Hungary and you'll be able to experience the fantastic scene for yourself.
Gergely Garami is a driver for Shuttle Direct on the Budapest airport to city route. They provide pre-booked shuttles to major destinations all over Europe. Wherever you travel, Shuttle Direct can make sure that you don't miss your car on your holiday abroad.
MALINGNANT GLIOMAS & ITS TREATMENT WITH CHEMOTHERAPEUTIC AGENT – TEMOZOLOMIDE
INTRODUCTION
Malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) occur more frequently than other types of primary CNS tumors, having a combined incidence of 5–8/100,000 population. Even with aggressive treatment using surgery, radiation, and chemotherapy, median reported survival is less than 1 year . Temozolomide, a new drug, has shown promise in treating malignant gliomas and other difficult-to-treat tumors. Temozolomide represents a new class of second-generation imidazotetrazine prodrugs that undergo spontaneous conversion under physiological conditions to the active alkylating agent MTIC. Thus, temozolomide does not require hepatic metabolism for activation .
Interest in temozolomide as an antitumor agent derives from its broad-spectrum antitumor activity in tumor models in mice . In vitro, temozolomide has demonstrated schedule-dependent antitumor activity against a variety of malignancies, including glioma, metastatic melanoma, and other difficult-to-treat cancers . In preclinical studies, temozolomide demonstrated distribution to all tissues, including penetration into the CNS; relatively low toxicity compared with its parent compound, mitozolomide; and antitumor activity against a broad range of tumor types, including glioma, melanoma, mesothelioma, sarcoma, lymphoma, leukemia, and carcinoma of the colon and ovary . Its demonstrated ability to cross the blood-brain barrier is of special interest with respect to its activity in CNS tumors .
In Phase 1 and 2 clinical studies conducted by the CRC (London, United Kingdom), temozolomide was absorbed rapidly, exhibited 100% p.o. bioavailability within 1–2 h of administration, and demonstrated antineoplastic activity in recurrent high-grade glioma, melanoma, and mycosis fungoides . Results of these trials showed that when temozolomide is administered p.o. once daily for 5 days in a 4-week cycle, it is well tolerated, producing mild-to-moderate toxicity that is both predictable and easily managed. The results also confirmed the ability of temozolomide to penetrate the CNS and indicated that temozolomide has considerable potential in treating gliomas and improving the QOL of patients with glioma . Additional Phase 1 studies have confirmed these results and have extended these observations to pediatric patients .
Temozolomide has been evaluated in a number of Phase 2 and 3 clinical trials for the treatment of glioblastoma multiforme, anaplastic astrocytoma, and malignant metastatic melanoma—malignancies for which there are no satisfactory therapies. On the basis of the results of these studies, temozolomide has been approved in the European Union for the treatment of patients with glioblastoma multiforme showing progression or recurrence after standard therapy. Recently, temozolomide received accelerated approval from the FDA for treatment of adult patients with anaplastic astrocytoma who have relapsed after treatment that included a nitrosurea drug (BCNU or CCNU) and procarbazine. Studies are under way to evaluate the combination of temozolomide with other chemotherapeutic agents and biochemotherapy in the treatment of malignant glioma and metastatic melanoma, respectively. This article reviews the mechanism of action of temozolomide as an anticancer agent and summarizes the most recent clinical studies of temozolomide for the treatment of malignant gliomas.
REFERENCES
- Avgeropoulos N. G., Batchelor T. T. New treatment strategies for malignant gliomas. Oncologist, 4: 209-224, 1999.
- Clark A. S., Deans B., Stevens M. F., Tisdale M. J., Wheelhouse R. T., Denny B. J., Hartley J. A. Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. J. Med. Chem., 38: 1493-1504, 1995.
- Stevens M. F. G., Hickman J. A., Langdon S. P., Chubb D., Vickers L., Stone R., Baig G., Goddard C., Gibson N. W., Slack J. A., Newton C., Lunt E., Fizames C., Lavelle F. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4( 3H)-one (CCRG 81045: M & B39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res., 47: 5846-5852, 1987.
- Friedman H. S., Dolan M. E., Pegg A. E., Marcelli S., Keir S., Catino J. J., Bigner D. D., Schold S. C., Jr. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res, 55: 2853-2857, 1995.
- Plowman J., Waud W. R., Koutsoukos A. D., Rubinstein L. V., Moore T. D., Grever M. R. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res., 54: 3793-3799, 1994.
- Pera M. F., Köberle B., Masters J. R. W. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. Br. J. Cancer, 71: 904-906, 1995.
- Carter C. A., Waud W. R., Plowman J. Responses of human melanoma, ovarian, and colon tumor xenografts in nude mice to oral temozolomide. Proc. Am. Assoc. Cancer Res., 35: 297 1994.
- Wedge S. R., Porteous J. K., Newlands E. S. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother. Pharmacol., 40: 266-272, 1997.
- Patel M., McCully C., Godwin K., Balis F. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc. Am. Soc. Clin. Oncol., 14: 461 1995.
10. Newlands E. S., Blackledge G. R. P., Slack J. A., Rustin G. J. S., Smith D. B., Stuart N. S. A., Quarterman C. P., Hoffman R., Stevens M. F. G., Brampton M. H., Gibson A. C. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer, 65: 287-291, 1992.
11. Bleehen N. M., Newlands E. S., Lee S. M., Thatcher N., Selby P., Calvert A. H., Rustin G. J. S., Brampton M., Stevens M. F. G. Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol., 13: 910-913, 1995.
12. O’Reilly S. M., Newlands E. S., Glaser M. G., Brampton M., Rice-Edwards J. M., Illingworth R. D., Richards P. G., Kennard C., Colquhoun I. R., Lewis P., Stevens M. F. G. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur. J. Cancer, 29A: 940-942, 1993.
13. Bower M., Newlands E. S., Bleehen N. M., Brada M., Begent R. J. H., Calvert H., Colquhoun I., Lewis P., Brampton M. H. Multicentre CRC Phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother. Pharmacol., 40: 484-488, 1997.
14. Paulsen F., Hoffmann W., Becker G., Belka C., Weinmann M., Classen J., Kortmann R. D., Bamberg M. Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. J. Cancer Res. Clin. Oncol., 125: 411-418, 1999.
15. Estlin E. J., Lashford L., Ablett S., Price L., Gowing R., Gholkar A., Kohler J., Lewis I. J., Morland B., Pinkerton C. R., Stevens M. C. G., Mott M., Stevens R., Newell D. R., Walker D., Dicks-Mireaux C., McDowell H., Reidenberg P., Statkevich P., Marco A., Batra V., Dugan M., Pearson A. D. J. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children’s Cancer Study Group. Br. J. Cancer, 78: 652-661, 1998.
16. Nicholson H. S., Krailo M., Ames M. M., Seibel N. L., Reid J. M., Liu-Mares W., Vezina L. G., Ettinger A. G., Reaman G. H. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children’s Cancer Group. J. Clin. Oncol., 16: 3037-3043, 1998.
17. Stevens M. F. G., Hickman J. A., Stone R., Gibson N. W., Baig G. U., Lunt E., Newton C. G. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d ]-1,2,3,5-tetrazin-4(3H)-one, a novel broad-spectrum antitumor agent. J. Med. Chem., 27: 196-201, 1984.
18. Hickman J. A., Stevens M. F. G., Gibson N. W., Langdon S. P., Fizames C., Lavelle F., Atassi G., Lunt E., Tilson R. M. Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (mitozolomide), a novel broad-spectrum agent. Cancer Res., 45: 3008-3013, 1985.
19. Horgan C. M. T., Tisdale M. J. An investigation into the mechanism of antitumour activity of a novel and potent antitumour agent, mitozolomide (CCRG 81010, M & B 39565; NSC 353451). Biochem. Pharmacol., 33: 2185-2192, 1984.
20. Gibson N. W., Hickman J. A., Erickson L. C. DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one. Cancer Res., 44: 1772-1775, 1984.
21. Gibson N. W., Erickson L. C., Hickman J. A. Effects of the antitumor agent 8-carbamoyl-3-(2-chloroethyl)imidaz[5,1-d]-1,2,3,5-tetrazin-4(3H)-one on the DNA of mouse L1210 cells. Cancer Res., 44: 1767-1771, 1984.
22. Horgan C. M. T., Tisdale M. J. Uptake and decomposition of a novel antitumour agent mitozolomide (CCRG 81010; M and B 39565; NSC 353451) in TLX5 mouse lymphoma in vitro. Biochem. Pharmacol., 34: 217-221, 1985.
23. Bull V. L., Tisdale M. J. Antitumour imidazotetrazines-XVI macromolecular alkylation by 3-substituted imidazotetrazinones. Biochem. Pharmacol., 36: 3215-3220, 1987.
24. Newlands E. S., Blackledge G., Slack J. A., Goddard C., Brindley C. J., Holden L., Stevens M. F. G. Phase I clinical trial of mitozolomide. Cancer Treat. Rep., 69: 801-805, 1985.
25. Stevens M. F., Newlands E. S. From triazines and triazenes to temozolomide. Eur. J. Cancer, 29A: 1045-1047, 1993.
26. Clark A. S., Stevens M. F. G., Sansom C. E., Schwalbe C. H. Anti-tumour imidazotetrazines. Part XXI. Mitozolomide and temozolomide: probes for the major groove of DNA. Anticancer Drug Des., 5: 63-68, 1990.
27. Lowe P. R., Sansom C. E., Schwalbe C. H., Stevens M. F. G., Clark A. S. Antitumor imidazotetrazines. 25. Crystal structure of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4-(3H)-one (temozolomide) and structural comparisons with the related drugs mitozolomide and DTIC. J. Med. Chem., 35: 3377-3382, 1992.
28. Spassova M. K., Golovinsky E. V. Pharmacobiochemistry of arylalkyltriazenes and their application in cancer chemotherapy. Pharmacol. Ther., 27: 333-352, 1985.
29. Denny B. J., Wheelhouse R. T., Stevens M. F. G., Tsang L. L. H., Slack J. A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry, 33: 9045-9051, 1994.
30. Liu L., Taverna P., Whitacre C. M., Chatterjee S., Gerson S. L. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin. Cancer Res., 5: 2908-2917, 1999.
31. Catapano C. V., Broggini M., Erba E., Ponti M., Mariani L., Citti L., D’Incalci M. In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res., 47: 4884-4889, 1987.
32. Deans B., Tisdale M. J. Antitumour imidazotetrazines XXVIII 3-methyladenine DNA glycosylase activity in cell lines sensitive and resistant to temozolomide. Cancer Lett., 63: 151-157, 1992.
33. Wedge S. R., Porteous J. K., Newlands E. S. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine–DNA alkyltransferase activity. Br. J. Cancer, 74: 1030-1036, 1996.
34. Wedge S. R., Porteus J. K., May B. L., Newlands E. S. Potentiation of temozolomide and BCNU cytotoxicity by O6-benzylguanine: a comparative study in vitro. Br. J. Cancer, 73: 482-490, 1996.
35. Dolan M. E., Mitchell R. B., Mummert C., Moschel R. C., Pegg A. E. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res., 51: 3367-3372, 1991.
36. Dolan M. E., Moschel R. C., Pegg A. E. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl. Acad. Sci. USA, 87: 5368-5372, 1990.
37. D’Atri S., Piccioni D., Castellano A., Tuorto V., Franchi A., Lu K., Christiansen N., Frankel S., Rustum Y. M., Papa G., Mandelli F., Bonmassar E. Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann. Oncol., 6: 389-393, 1995.
38. Drummond J. T., Li G. M., Longley M. J., Modrich P. Isolation of an hMSH2–p160 heterodimer that restores DNA mismatch repair to tumor cells. Science (Washington, DC), 268: 1909-1912, 1995.
39. Palombo F., Gallinari P., Iaccarino I., Lettieri T., Hughes M., D’Arrigo A., Truong O., Hsuan J. J., Jiricny J. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science (Washington, DC), 268: 1912-1914, 1995.
40. Li G. M., Modrich P. Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs. Proc. Am. Assoc. Cancer Res., 92: 1950-1954, 1995.
41. Karran P., Macpherson P., Ceccotti S., Dogliotti E., Griffin S., Bignami M. O6-methylguanine residues elicit DNA repair synthesis by human cell extracts. J. Biol. Chem., 268: 15878-15886, 1993.
42. Taverna P., Catapano C. V., Citti L., Bonfanti M., D’Incalci M. Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anticancer Drugs, 3: 401-405, 1992.
43. Karran P., Hampson R. Genomic instability and tolerance to alkylating agents. Cancer Surv., 28: 69-85, 1996.
44. Karran P., Bignami M. Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Res., 20: 2933-2940, 1992.
45. Tentori L., Graziani G., Gilberti S., Lacal P. M., Bonmassar E., D’Atri S. Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia, 9: 1888-1895, 1995.
46. Bianchi R., Citti L., Beghetti R., Romani L., D’Incalci M., Puccetti P., Fioretti M. C. O6-Methylguanine-DNA methyltransferase activity and induction of novel immunogenicity in murine tumor cells treated with methylating agents. Cancer Chemother. Pharmacol., 29: 277-282, 1992.
47. Allegrucci M., Fuschiotti P., Puccetti P., Romani L., Fioretti M. C. Changes in the tumorigenic and metastatic properties of murine melanoma cells treated with a triazene derivative. Clin. Exp. Metastasis, 7: 329-341, 1989.
48. Tentori L., Leonetti C., Aquino A. Temozolomide reduces the metastatic potential of Lewis lung carcinoma (3LL) in mice: role of -6 integrin phosphorylation. Eur. J. Cancer, 31A: 746-754, 1995.
49. Tisdale M. J. Antitumour imidazotetrazines—XVIII. Modification of the level of 5-methylcytosine in DNA by 3-substituted imidazotetrazinones. Biochem. Pharmacol., 38: 1097-1101, 1989.
50. Hepburn P. A., Tisdale M. J. Growth suppression by DNA from cells treated with imidazotetrazinones. Biochem. Pharmacol., 41: 339-343, 1991.
51. Zucchetti M., Catapano C. V., Filippeschi S., Erba E., D’Incalci M. Temozolomide induced differentiation of K562 leukemia cells is not mediated by gene hypomethylation. Biochem. Pharmacol., 38: 2069-2075, 1989.
52. Pegg A. E., Dolan M. E., Moschel R. C. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog. Nucleic Acid Res. Mol. Biol., 51: 167-223, 1995.
53. D’Incalci M., Citti L., Taverna P., Catapano C. V. Importance of the DNA repair enzyme O6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy. Cancer Treat. Rev., 15: 279-292, 1988.
54. Pegg A. E., Byers T. L. Repair of DNA containing O6-alkylguanine. FASEB J., 6: 2302-2310, 1992.
55. Tisdale M. J. Antitumor imidazotetrazines–XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem. Pharmacol., 36: 457-462, 1987.
56. Baer J. C., Freeman A. A., Newlands E. S., Watson A. J., Rafferty J. A., Margison G. P. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br. J. Cancer, 67: 1299-1302, 1993.
57. Redmond S. M., Joncourt F., Buser K., Ziemiecki A., Altermatt H. J., Fey M., Margison G., Cerny T. Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res., 51: 2092-2097, 1991.
58. Franchi A., Papa G., D’Atri S., Piccioni D., Masi M., Bonmassar E. Cytotoxic effects of dacarbazine in patients with acute myelogenous leukemia: a pilot study. Haematologica, 77: 146-150, 1992.
59. Wang G., Weiss C., Sheng P., Bresnick E. Retrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents. Biochem. Pharmacol., 51: 1221-1228, 1996.
60. Walker M. C., Masters J. R. W., Margison G. P. O6-alkylguanine-DNA-alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines. Br. J. Cancer, 66: 840-843, 1992.
61. Bobola M. S., Tseng S. H., Blank A., Berger M. S., Silber J. R. Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin. Cancer Res., 2: 735-741, 1996.
62. Liu L., Markowitz S., Gerson S. L. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res., 56: 5375-5379, 1996.
63. Friedman H. S., Johnson S. P., Dong Q., Schold S. C., Rasheed B. K. A., Bigner S. H., Ali-Osman F., Dolan E., Colvin O. M., Houghton P., Germain G., Drummond J. T., Keir S., Marcelli S., Bigner D. D., Modrich P. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res., 57: 2933-2936, 1997.
64. Tisdale M. J. Antitumour imidazotetrazines-XI: effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one [CCRG 81045; M and B 39831 NSC 362856] on poly(ADP-ribose) metabolism. Br. J. Cancer, 52: 789-792, 1985.
65. Durkacz B. W., Omidiji O., Gray D. A., Shall S. (ADP-ribose)n participates in DNA excision repair. Nature (Lond.), 283: 593-596, 1980.
66. Boulton S., Pemberton L. C., Porteous J. K., Curtin N. J., Griffin R. J., Golding B. T., Durkacz B. W. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br. J. Cancer, 72: 849-856, 1995.
67. Wu Z., Chan C. L., Eastman A., Bresnick E. Expression of human O6-methylguanine-DNA methyltransferase in Chinese hamster ovary cells and restoration of cellular resistance to certain N-nitroso compounds. Mol. Carcinog., 4: 482-488, 1991.
68. Tentori L., Turriziani M., Franco D., Serafino A., Levati L., Roy R., Bonmassar E., Graziani G. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia, 13: 901-909, 1999.
69. Imperatori L., Damia G., Taverna P., Garattini E., Citti L., Boldrini L., D’Incalci M. 3T3 NIH murine fibroblasts and B78 murine melanoma cells expressing the Escherichia coli N3-methyladenine-DNA glycosylase I do not become resistant to alkylating agents. Carcinogenesis (Lond.), 15: 533-537, 1994.
70. Friedman H. S., Dolan M. E., Moschel R. C., Pegg A. E., Felker G. M., Rich J., Bigner D. D., Schold S. C. J. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J. Natl. Cancer Inst., 84: 1926-1931, 1992.
71. Dolan M. E., Pegg A. E. O6-benzylguanine and its role in chemotherapy. Clin. Cancer Res., 3: 837-847, 1997.
72. Middleton M. R., Kelly J., Thatcher N., Donnelly D. J., McElhinney R. S., McMurry T. B., McCormick J. E., Margison G. P. O6-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int. J. Cancer, 85: 248-252, 2000.
73. Wedge S. R., Newlands E. S. O6-Benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br. J. Cancer, 73: 1049-1052, 1996.
74. Fairbairn L. J., Watson A. J., Rafferty J. A., Elder R. H., Margison G. P. O6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp. Hematol., 23: 112-116, 1995.
75. Chinnasamy N., Rafferty J. A., Hickson I., Ashby J., Tinwell H., Margison G. P., Dexter T. M., Fairbairn L. J. O6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood, 89: 1566-1573, 1997.
76. Chinnasamy N., Rafferty J., Lashford L., Chinnasamy D., Margison G., Thatcher N., Dexter T., Fairbairn L. Protection of committed murine haemopoietic progenitors against BCNU toxicity does not predict protection of primitive, multipotent spleen colony-forming cells—implications for chemoprotective gene therapy. Leukemia, 13: 1776-1783, 1999.
77. Reese J. S., Davis B. M., Liu L., Gerson S. L. Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide. Clin. Cancer Res., 5: 163-169, 1999.
78. Chinnasamy N., Rafferty J. A., Hickson I., Lashford L. S., Longhurst S. J., Thatcher N., Margison G. P., Dexter T. M., Fairbairn L. J. Chemoprotective gene transfer II: multilineage in vivo protection of haemopoiesis against the effects of an antitumour agent by expression of a mutant human O6-alkylguanine-DNA alkyltransferase. Gene Ther., 5: 842-847, 1998.
79. Hickson I., Fairbairn L. J., Chinnasamy N., Lashford L. S., Thatcher N., Margison G. P., Dexter T. M., Rafferty J. A. Chemoprotective gene transfer I: transduction of human haemopoietic progenitors with O6-benzylguanine-resistant O6-alkylguanine-DNA alkyltransferase attenuates the toxic effects of O6-alkylating agents in vitro. Gene Ther., 5: 835-841, 1998.
80. Hammond L. A., Eckardt J. R., Baker S. D., Eckhardt S. G., Dugan M., Forral K., Reidenberg P., Statkevich P., Weiss G. R., Rinaldi D. A., Von Hoff D. D., Rowinsky E. K. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J. Clin. Oncol., 17: 2604 1999.
81. Brock C. S., Newlands E. S., Wedge S. R., Bower M., Evans H., Colquhoun I., Roddie M., Glaser M., Brampton M. H., Rustin G. J. S. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res., 58: 4363-4367, 1998.
82. Baker S. D., Wirth M., Statkevich P., Reidenberg P., Alton K., Sartorius S. E., Dugan M., Cutler D., Batra V., Grochow L. B., Donehower R. C., Rowinsky E. K. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin. Cancer Res., 5: 309-317, 1999.
83. Dhodapkar M., Rubin J., Reid J. M., Burch P. A., Pitot H. C., Buckner J. C., Ames M. M., Suman V. J. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin. Cancer Res., 3: 1093-1100, 1997.
84. Brada M., Judson I., Beale P., Moore S., Reidenberg P., Statkevich P., Dugan M., Batra V., Cutler D. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br. J. Cancer, 81: 1022-1030, 1999.
85. Beale P., Judson I., Moore S., Statkevich P., Marco A., Cutler D. L., Reidenberg P., Brada M. Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. Cancer Chemother. Pharmacol., 44: 389-394, 1999.
86. Feun L. G., Savaraj N., Landy H. J. Drug resistance in brain tumors. J. Neurooncol., 20: 165-176, 1994.
87. Prados M. D., Russo C. Chemotherapy of brain tumors. Semin. Surg. Oncol., 14: 88-95, 1998.
88. Pech I. V., Peterson K., Cairncross J. G. Chemotherapy for brain tumors. Oncology, 12: 537-553, 1998
89. Rodriguez L. A., Levin V. A. Does chemotherapy benefit the patient with a central nervous system glioma? [see comments]. Oncology (Huntingt), 1: 29-36, 1987.
90. Newlands E. S., O’Reilly S. M., Glaser M. G., Bower M., Evans H., Brock C., Brampton M. H., Colquhoun I., Lewis P., RiceEdwards J. M., Illingworth R. D., Richards P. G. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur. J. Cancer, 32A: 2236-2241, 1996.
91. Yung A., Levin V. A., Albright R., Olson J., Fredericks R., Fink K., Prados M., Brada M., Spence A., Brunner J., Yue N., Dugan M. H., Zaknoen S., Temodal Brain Tumor Group. Randomized trial of temodal (TEM) vs. procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse. Proc. Am. Soc. Clin. Oncol., 18: 139 1999.
92. Yung W. K., Prados M. D., Yaya-Tur R., Rosenfeld S. S., Brada M., Friedman H. S., Albright R., Olson J., Chang S. M., O’Neill A. M., Friedman A. H., Bruner J., Yue N., Dugan M., Zaknoen S., Levin V. A. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J. Clin. Oncol., 17: 2762 1999.
93. Friedman H. S., McLendon R. E., Kerby T., Dugan M., Bigner S. H., Henry A. J., Ashley D. M., Krischer J., Lovell S., Rasheed K., Marchev F., Seman A. J., Cokgor I., Rich J., Stewart E., Colvin O. M., Provenzale J. M., Bigner D. D., Haglund M. M., Friedman A. H., Modrich P. L. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J. Clin. Oncol., 16: 3851-3857, 1998.
About the Author
1970's I think children's TV with a gang of kids and a red double decker bus and 1 girl had a stuffed tiger!!
I have very fond memories of a children's TV prog. that was about a gang of children from London I think, that had a club house in a red double decker bus. The youngest was a girl that had a stuffed toy called Tiger. Does anyone else remember this and do they know what it was called, it is driving me mad!!!!
"(Here Come)The Double Deckers". See link.
London Review: 'Love Never Dies'
LONDON -- Unlike lightning, Andrew Lloyd Webber's "Phantom" does strike twice.
Thanks for visiting!
![AMON DUUL - Live in London [Bonus Tracks] CD PROG ROCK](http://thumbs.ebaystatic.com/pict/250977523976_0.jpg)
US $11.95
